Meeting
2020 ASCO Virtual Scientific Program
AST-008: A novel approach to TLR9 agonism with PD-1 blockade for anti-PD-1 refractory Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (CSCC).
Authors
Mohammed M. Milhem
Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA
Mohammed M. Milhem , Cesar Augusto Perez , Glenn J. Hanna , Trisha Michel Wise-Draper , Shailender Bhatia , Alice Susannah Bexon , Weston L Daniel , Steven O'Day
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT03684785
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS3164)
DOI
10.1200/JCO.2020.38.15_suppl.TPS3164
Abstract #
TPS3164
Poster Bd #
228
Abstract Disclosures
Similar Posters
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM).
First Author: Marc Isamu Uemura
Poster
2020 Gastrointestinal Cancers Symposium
![Phase Ib study to test the safety and activity of pembrolizumab (anti-PD-1) and trebananib (angiopoietin-2 inhibitor [Ang-2]) in patients with advanced solid tumors: Updated analysis of the colorectal cancer (CRC) cohort.](https://d201v5jt9ylckg.cloudfront.net/255/14596/182760/182760_poster_pv.jpg)
Phase Ib study to test the safety and activity of pembrolizumab (anti-PD-1) and trebananib (angiopoietin-2 inhibitor [Ang-2]) in patients with advanced solid tumors: Updated analysis of the colorectal cancer (CRC) cohort.
First Author: Osama E. Rahma
Poster
2019 ASCO Annual Meeting
A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy.
First Author: Shubham Pant
Poster
2018 ASCO Annual Meeting
A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.
First Author: Adi Diab